Affymax to Reduce Headcount by 75%; Will Evaluate Strategic Alternatives

Affymax, Inc. (Nasdaq: AFFY ) today announced that it will reduce its workforce as part of a plan to focus the company's resources on the ongoing investigation of reported hypersensitivity reactions in patients receiving OMONTYS® (peginesatide) Injection following the nationwide voluntary recall of product from the market . This